Rather than uncertainty about what the Presidency of Donald Trump might mean for drug prices, many pharma and biotech stocks jumped considerably after the Republican nominee gained a shock election victory over Democrat Hillary Clinton.
Many US drugmakers leapt overnight, including pharma giants Merck & Co (NYSE: MRK), which was nearly 5% up on the previous evening after an hour’s trading on Tuesday, and Pfizer (NYSE: PFE), which was trading almost 8% higher at the same time. This was after they had settled down having initially opening at even higher rates.
US biotechs were also up, with Amgen (Nasdaq: AMGN) and Gilead more than 4% higher, and Regeneron rising 8%.
Internationally it was a similar story, with Swiss pharma giants Novartis (NOVN: VX) and Roche (ROG: SIX) climbing 5% and France’s Sanofi (Euronext: SAN) up 4%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze